NCT06615414Not yet recruiting
Cardiovascular Manifestations in Ph-negative MPN
Clinical and Subclinical Cardiovascular Manifestations in Philadelphia Negative Myeloproliferative Neoplasms
Source: ClinicalTrials.gov · Last updated 26 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary aim of this research is to investigate the clinical and subclinical cardiovascular complications and its relationship with myeloproliferative neoplasms seeking to assess incidence, prevalence and severity in comparison to healthy group and analyze potential risk factors including genetic mutations, inflammatory markers and hematological parameters
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 15 Sept 2024
- Start date
- Oct 2024
- Primary completion date
- Oct 2028
- Lead sponsor
- Assiut University
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT06615414
What you commit to
- Study type: Observational
- Planned participants: 80
- From Oct 2024 to the primary completion date, Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with secondary erythrocytosis or thrombocytosis due to other underlying conditions (e.g., chronic hypoxia, tumors) will be excluded.
- Patients who have experienced a myocardial infarction, stroke, heart failure, Hypertension, or significant cardiovascular event before diagnosis of MPN
- Patients with severe comorbid conditions that could confound results, such as:
- Severe renal or hepatic impairment
- Active malignancies other than MPN
Age
- at age group below 18 years old.
Other
- Pregnant or lactating women should be excluded due to potential risks associated with cardiovascular evaluations.
- who refused to participate in the study.
Who the study is looking for
- patients with confirmed diagnosis of myeloproliferative neoplasms of one of the following:
- Essential thrombocythemia (ET)
- Polycythemia vera (PV)
- Primary myelofibrosis (PMF)
- Adults aged 18 years and older.
- who accept to participate in the study in Assiut university hospital.
Age in the registry: 18 years to 75 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.